BIOMAT Database Logo BIOMAT Database Logo

Bartter's syndrome: urinary prostaglandin E-like material and kallikrein; indomethacin effects. 1977

P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius

The urinary excretions of prostaglandin E-like material (iPGE) and kallikrein were measured in two children with Bartter's syndrome. Urinary iPGE excretion was three and 10 times greater than normal, and urinary kallikrein was five and 10 times greater than normal in the two subjects. Furthermore, excretions of iPGE and kallikrein were highly correlated (P less than 0.005) with each other before and during treatment with indomethacin, a prostaglandin synthetase inhibitor. Indomethacin significantly (P less than 0.001) reduced urinary iPGE, urinary kallikrein, and plasma renin activity, while increasing the sensitivity to intravenous angiotensin II and the serum potassium to normal. The results confirm that renal prostaglandins may be involved in the pathogenesis of Bartter's syndrome and suggest that renal prostaglandins and the kallikrein-kinin system are linked.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000450 Aldosterone A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Aldosterone, (+-)-Isomer,Aldosterone, (11 beta,17 alpha)-Isomer
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Urinary excretion of prostaglandin E like material and kallikrein: effects of furosemide.
September 1979, Prostaglandins,
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Bartter's syndrome with normal urinary excretion of prostaglandin E: therapeutic effects of propranolol, spironolactone, indomethacin and potassium chloride.
June 1980, The Tohoku journal of experimental medicine,
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Urinary kallikrein excretion in Bartter's syndrome.
November 1976, The Journal of clinical endocrinology and metabolism,
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Effect of indomethacin on urinary kallikrein excretion in Bartter's syndrome of the adult.
January 1981, Journal of endocrinological investigation,
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Prostaglandin E excretion and inhibition of prostaglandin synthesis in Bartter's syndrome.
November 1978, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Indomethacin for Bartter's syndrome.
December 1976, Lancet (London, England),
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
[Indomethacin in Bartter's syndrome].
June 1978, Revista clinica espanola,
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Bartter's syndrome: effect of indomethacin on prostaglandins, urinary kallikrein, renin-angiotensin-aldosterone system, and the response to angiotensin II antagonist.
August 1980, Endocrinologia japonica,
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Neonatal Bartter's syndrome with hyperkalemia and normal urinary prostaglandin E2.
June 1997, Pediatric nephrology (Berlin, Germany),
P V Halushka, and H Wohltmann, and P J Privitera, and G Hurwitz, and H S Margolius
Some aspects of urinary kallikrein in a patient with Bartter's syndrome.
January 1979, Advances in experimental medicine and biology,
Copied contents to your clipboard!